Autres langues Opsens Inc. Toronto S.E.

Actions

CA6838231083

Equipement et technologie médicale avancés

Cours en clôture Toronto S.E.			Varia. 5j.	Varia. 1 janv.
- ^CAD	-.--%		-.--%	-

12/12/23	Haemonetics finalise l'acquisition d'OpSens pour 255 millions de dollars	MT
12/12/23	Haemonetics Corporation (NYSE : HAE) a complété l'acquisition d'Opsens Inc. (TSX : OPS).	CI

Autres langues

12/12/23	Haemonetics Completes $255 Million Acquisition of OpSens
12/12/23	OpSens Brief: NYSE's Haemonetics Completed Acquisition
12/12/23	HAEMONETICS COMPLETES ACQUISITION OF OPSENS
12/12/23	Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS) for approximately CAD 330 million.
08/12/23	OpSens Receives Final Order For Its Acquisition By NYSE's Haemonetics
08/12/23	OpSens Brief: Says Received Final Order For Its Acquisition By NYSE's Haemonetics
08/12/23	OPSENS RECEIVES FINAL ORDER FOR ARRANGEMENT WITH HAEMONETICS
01/12/23	Opsens Shareholders Approve Arrangement With Haemonetics
01/12/23	OPSENS' SHAREHOLDERS APPROVE ARRANGEMENT WITH HAEMONETICS
28/11/23	OpSens Brief: In connection with prior announced acquisition by Haemonetics Obtained Regulatory Clearance of Arrangement in the US and Canada; Regulatory Approvals Condition Satisfied
28/11/23	OPSENS OBTAINS REGULATORY CLEARANCE OF ARRANGEMENT IN THE UNITED STATES AND CANADA; REGULATORY APPROVALS CONDITION SATISFIED
22/11/23	Opsens Inc. Reports Earnings Results for the Full Year Ended August 31, 2023
22/11/23	Opsens : Management’s Discussion & analysis for the year 2023
22/11/23	OpSens Fiscal Q4 Loss Narrows as Sales Rise 57% Ahead of Acquisition by Haemonetics
22/11/23	OPSENS ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIAL RESULTS
22/11/23	Opsens Inc. Reports Earnings Results for the Fourth Quarter Ended August 31, 2023
13/11/23	OpSens Brief: ISS Recommends Shareholders Vote For Opsens Inc. Plan of Arrangement with NYSE's Haemonetics
13/11/23	INDEPENDENT PROXY ADVISORY FIRM ISS RECOMMENDS SHAREHOLDERS VOTE "FOR" OPSENS INC. PLAN OF ARRANGEMENT WITH HAEMONETICS CORPORATION
02/11/23	OPSENS RECEIVES INTERIM ORDER AND FILES MANAGEMENT INFORMATION CIRCULAR IN CONNECTION WITH SPECIAL MEETING OF SHAREHOLDERS
23/10/23	OPSENS ANNOUNCES THE POSITIVE CLINICAL RESULTS FROM THE SAFE-TAVI STUDY WITH SAVVYWIRE IN EUROPE
17/10/23	OpSens to Participate in the Transcatheter Cardiovascular Therapeutics Conference (TCT) in San Francisco October 23 - 26, 2023
11/10/23	Barrington Research's Initial Take on Haemonetics' Acquisition of OpSens
11/10/23	Needham on Opsens Being Acquired by Haemonetics
10/10/23	Toronto Stocks Advance; Opsens Soars on C$345 Million Buyout Deal
10/10/23	OpSens Signed Definitive Agreement For Its Acquisition By NYSE's Haemonetics